Brief: Vaxart Doses First Subject In The Phase 2 Clinical Trial Of Its Bivalent Norovirus Candidate
14/02/2023 13:20
Feb 14 (Reuters) - Vaxart Inc VXRT.O :
* VAXART DOSES FIRST SUBJECT IN THE PHASE 2 CLINICAL TRIAL
OF ITS
BIVALENT NOROVIRUS CANDIDATE
* VAXART INC - VAXART EXPECTS TO REPORT TOPLINE DATA FROM
PHASE 2
STUDY IN MID-2023
Source text for Eikon: ID:nGNX93c93F
Further company coverage: VXRT.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts